ZYVERSA THERAPEUTICS, INC. — Earnings
Most recent reported period: FY2025 (Q3) (filed for period ending 2025-09-30) · sourced from SEC EDGAR
Next earnings (estimated): Tue, December 30, 2025 — 122 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | — | — | — | — | — |
| 2025-09-30 | $-131K | — | $-20M | — | 15799.1% |
| 2025-07-24 | — | — | — | — | — |
| 2025-06-30 | $-130K | ↓-224100.0% | $-2M | ↑+20.0% | 1572.0% |
| 2025-03-31 | $-120K | ↓-118275.2% | $-2M | ↑+20.2% | 1793.7% |
| 2024-12-31 | — | — | — | — | — |
| 2024-09-30 | $-132K | ↓-62583.3% | $-2M | ↑+17.3% | 1724.2% |
| 2024-06-30 | $-58 | ↑+81.5% | $-3M | ↑+96.5% | 4748237.9% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q3)
Revenue
$0
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
ZVSA Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyZVSA Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics